NCT03217396Recruiting
Biomarkers of Synaptic Damage in Multiple Sclerosis
Identification of New Biomarkers Useful to Define the Course of Multiple Sclerosis and Study of the Mechanisms That Promote Synaptic Damage
Source: ClinicalTrials.gov · Last updated 28 Oct 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
A prospective and retrospective cohort study of about five years will be performed on blood and cerebrospinal fluid samples taken for diagnostic reasons from recruited patients within the Neuromed Neurology Unit. Subjects with other chronic neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD), and healthy subjects subjected to blood sampling and / or lumbar puncture for clinical reasons will be recruited As control groups.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 12 Jul 2017
- Start date
- 22 Nov 2017
- Primary completion date
- 1 Sept 2026
- Lead sponsor
- Neuromed IRCCS
- NCT number
- NCT03217396
What you commit to
- Study type: Observational
- Planned participants: 300
- From 22 Nov 2017 to the primary completion date, 1 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Significant clinical conditions in addition to SM or other chronic neurodegenerative diseases including latent viral infections
Lab values
- Altered basal blood count
Other
- Inability to provide informed written consent
- Pregnancy or lactation
- Contraindications for the execution of magnetic resonance imaging with gadolinium
Who the study is looking for
- Male and female patients (age between 18 and 65 years)
- Diagnosis of MS in accordance with McDonald's (2010 rev) criteria,
- EDSS between 0 and 5.5 (included),
- Patients able to provide informed consent to participation in the study
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS Neuromed Coordinator of this site? Confirm its status | Pozzilli | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.